The non-cash exchange of CERO notes for convertible preferred stock adds a large dilutive overhang with no operating cash infusion. Monitor for stockholder approval timeline and any early conversion activity that could pressure the stock. The alternate conversion rights at a discount to VWPA create a structural downward bias if the stock trades below $2.1888.
Price Chart
Executive Summary
SRX Global issued $2.86M of Series C convertible preferred stock to accredited investors in exchange for assignment of CERO Therapeutics promissory notes, with no new cash proceeds. The preferred stock carries a fixed conversion price of $2.1888 per common share and includes alternate conversion rights at a discount to market price after stockholder approval, creating significant future dilution overhang.
Key Financial Metrics
Key Facts
- Sold 3,579 shares of Series C convertible preferred stock at $1,000 stated value per share for total consideration of $2,862,500
- Purchase price satisfied by assignment of Convertible Grid Promissory Notes issued by CERO Therapeutics Holdings, Inc. (aggregate original principal $2,812,500)
- Fixed conversion price of $2.1888 per common share; alternate optional conversion at 95% of 5-day VWAP and alternate triggering event conversion at 90% of 5-day VWAP (both after stockholder approval)
- Company must seek stockholder approval for issuance of all common shares upon conversion and warrant exercise per NYSE American rules
- Registration rights agreement requires filing of resale registration statement for conversion shares and warrant shares
- Company may redeem all outstanding Series C preferred at 115% of the greater of conversion amount or market-linked value
Financial Impact
Up to ~1.6M common shares issuable upon full conversion of Series C preferred at $2.1888/share, representing material dilution relative to current $35M market cap
Risk Factors
- Significant dilution from conversion of Series C preferred into common stock
- Alternate conversion at 95%/90% of VWPA could accelerate selling pressure
- No new cash raised — the transaction merely swaps one illiquid asset for equity-linked securities
- Stockholder approval required for full conversion rights; failure could trigger triggering events with penalty provisions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-040642 |
| Document: 0001493152-26-040642-index.html | 0001493152-26-040642 |
| Document: 0001493152-26-040642.txt | 0001493152-26-040642 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $1.51 $1.60 | ▲ +5.96% | ▲ +6.62% | $1.61 (+6.62%) |
Sep 2, 2026 4w ago | 8-K | $1.56 $1.59 | ▲ +1.92% | ▲ +3.07% | $1.61 (+3.21%) |
Aug 28, 2026 5w ago | 8-K | $1.68 $1.59 | ▲ +5.65% | ▲ +5.51% | $1.61 (+4.17%) |
Aug 19, 2026 6w ago | 8-K | $1.87 $1.84 | ▼ −1.60% | ▼ −1.22% | $1.61 (−13.90%) |
Aug 4, 2026 8w ago | Press Release | $1.37 $1.84 | ▲ +34.31% | ▲ +34.41% | $1.61 (+17.52%) |
Aug 3, 2026 8w ago | Press Release | $1.44 $1.73 | ▲ +20.14% | ▲ +18.11% | $1.61 (+11.81%) |
Jul 30, 2026 9w ago | Press Release | $1.48 $1.43 | ▼ −3.38% | ▼ −7.00% | $1.61 (+8.78%) |
Jul 28, 2026 9w ago | 8-K | $1.48 $1.44 | ▲ +2.70% | ▲ +4.97% | $1.61 (−8.78%) |
Jul 16, 2026 11w ago | 8-K | $2.41 $1.80 | ▼ −25.31% | ▼ −23.64% | $1.61 (−33.20%) |
Jul 16, 2026 11w ago | Press Release | $2.41 $1.80 | ▼ −25.31% | ▼ −23.64% | $1.61 (−33.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access